Log in

NASDAQ:BLFS - BioLife Solutions Stock Price, Forecast & News

$9.39
-0.69 (-6.85 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$9.02
Now: $9.39
$9.79
50-Day Range
$8.36
MA: $12.96
$16.32
52-Week Range
$7.37
Now: $9.39
$21.18
Volume125,543 shs
Average Volume289,175 shs
Market Capitalization$192.03 million
P/E Ratio21.34
Dividend YieldN/A
Beta1.21
BioLife Solutions, Inc. develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death. The company offers CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing; and HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 to cryopreserve stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including cell and gene therapy companies, research institutions, hospital-based stem cell transplant centers, cell therapy contract manufacturing organizations, contract development manufacturing organizations, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Read More
BioLife Solutions logo

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.37 million
Cash Flow$0.16 per share
Book Value$2.33 per share

Profitability

Net Income$11.06 million

Miscellaneous

Employees54
Market Cap$192.03 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.


BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

How has BioLife Solutions' stock been impacted by COVID-19 (Coronavirus)?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLFS stock has decreased by 23.3% and is now trading at $9.39. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioLife Solutions?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioLife Solutions.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for BioLife Solutions.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions Inc (NASDAQ:BLFS) posted its earnings results on Wednesday, March, 11th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.04. The medical equipment provider had revenue of $8.30 million for the quarter, compared to analysts' expectations of $8.72 million. BioLife Solutions had a net margin of 40.42% and a return on equity of 3.33%. View BioLife Solutions' earnings history.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2020 After-Hours earnings guidance on Wednesday, March, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $48-53 million, compared to the consensus revenue estimate of $52.35 million.

What price target have analysts set for BLFS?

8 brokerages have issued 1 year price objectives for BioLife Solutions' shares. Their forecasts range from $17.00 to $26.00. On average, they expect BioLife Solutions' share price to reach $22.88 in the next year. This suggests a possible upside of 143.6% from the stock's current price. View analysts' price targets for BioLife Solutions.

Has BioLife Solutions been receiving favorable news coverage?

News coverage about BLFS stock has trended very positive on Sunday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioLife Solutions earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutBioLife Solutions.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Micron Technology (MU), Amarin (AMRN), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Square (SQ), Twilio (TWLO), Cara Therapeutics (CARA) and Crispr Therapeutics (CRSP).

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
  • Mr. Roderick de Greef, CFO & Sec. (Age 59)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
  • Ms. Karen Foster, VP of Operations (Age 59)
  • Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Casdin Capital LLC (12.07%), Russell Investments Group Ltd. (2.72%), Driehaus Capital Management LLC (2.33%), Royce & Associates LP (1.08%), Essex Investment Management Co. LLC (1.04%) and Parkman Healthcare Partners LLC (0.81%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View institutional ownership trends for BioLife Solutions.

Which institutional investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Cadence Capital Management LLC, Schonfeld Strategic Advisors LLC, Perkins Capital Management Inc., Russell Investments Group Ltd., Driehaus Capital Management LLC, Bank of America Corp DE, and Penbrook Management LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Michael Rice, Raymond W Cohen, Todd Berard, and Walter Villiger. View insider buying and selling activity for BioLife Solutions.

Which institutional investors are buying BioLife Solutions stock?

BLFS stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Roubaix Capital LLC, Marshall Wace LLP, Bank of Montreal Can, Casdin Capital LLC, Isthmus Partners LLC, Goldman Sachs Group Inc., and Franklin Resources Inc.. View insider buying and selling activity for BioLife Solutions.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $9.39.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $192.03 million and generates $27.37 million in revenue each year. The medical equipment provider earns $11.06 million in net income (profit) each year or $0.08 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe. View additional information about BioLife Solutions.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is http://www.biolifesolutions.com/.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]


MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel